Click chemistry uses endogenous acrolein to activate cancer prodrug

Japan-based chemists have developed a strategy for activating an anticancer prodrug that takes advantage of elevated levels of endogenous acrolein at tumour sites. This could reduce side effects, which are often serious drawbacks of cancer therapy, by targeting the drug release directly into the cancerous tissue to avoid healthy cells.